Development of newer approaches to male contraception: prospects of availability for mass application in the near future by Jagannadha Rao, A.
243
Journal of Reproduction & Contraception (2005) 16 (4):243-254
Development of Newer Approaches to Male Contraception:
Prospects of Availability for Mass Application in the Near
Future
A. Jagannadha Rao
Department of Biochemistry, Indian Institute of Science, Bangalore 560 012, India
Corresponding author: A Jagannadha Rao;  Tel: +91-80-3092308/3608660;
            Fax: +91-80-3600999/3600814;  E-mail: ajrao@biochem.iisc.ernet.in
Progress in development of a simple, effective reversible male contraceptive has
been difficult due to the indispensable role of testosterone in spermatogenesis and
maintenance of secondary sexual characters.  Efforts are in progress to develop methods,
which do not interfere with testosterone production. These include blockade of FSH
action by immunization against FSH or FSHR, and interfere with sperm maturation by
interfering with estrogen action or by immunization against epididymal or sperm specific
proteins. An evaluation of these various approaches for practical application is also
presented.
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Introduction
The need for control of population explosion in the developing countries is not necessary to
over emphasize.  Unfortunately due to lack of acceptable methods of fertility control for
males, the entire burden of limiting the family size is borne by the female. This is mainly due
to male dominated social system in some of the underdeveloped countries and the availability
of choice of contraception methods for use by the female, in contrast to the limited methods
available for use by the male[1].
It is distressing to note that in spite of concerted efforts of several agencies for over 40
years, it has not been possible to develop an acceptable method of contraception for use by
male other than condom and vasectomy. This has been mainly due to the requirement that
any method developed for male contraception should not interfere with libido and secondary
sexual characteristics which are dependent on testosterone.
·R E V I E W·
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In the case of male, the important hormones needed for reproduction are follicle stimu-
lating hormone (FSH), lutenizing hormone (LH) and testosterone (T).  FSH acts on Sertoli
cells and LH acts on Leydig cells to produce T which also acts on Sertoli cells. In all species
so far studied, T is indispensable for normal spermatogenesis.
It is quite easy to interfere with the action of T and thus sperm production by feed back
inhibition of hypothalamo-pituitary axis by administering T to males[2].  This will be similar to
the inhibition of pituitary LH which is needed for ovulation in the female by administering the
female pill, which is now very widely used all over the world by women. However, in the
case of male, inhibition of T production also interferes with libido which is completely
unacceptable. Thus over the last 40 years efforts have been going on to develop a method of
contraception for male which does not interfere with T levels.  So far, 4 such methods are
being considered and in the present paper an attempt is made to evaluate them and comment
on the feasibility of practical application of these approaches.
Interfering with the action of FSH
The process of reproduction in all mammals is regulated by the hypothalamic gonadot-
ropin releasing hormone (GnRH) which regulates the production of pituitary gonadotrophins
FSH and LH which in turn act on testis.  FSH acts on Sertoli cells and LH acts on Leydig
cells to produce T; both FSH and T together act on Sertoli cells to produce a variety of
factors. These factors together act on germ cells to regulate the process of spermatogenesis
which culminates in the production of spermatozoa.
Pioneering studies by Moudgal, et al.[3] have established that FSH is obligatory for
initiation and maintenance of quantitative spermatogenesis in primates. Using adult male
bonnet monkeys Macaca radiata as a model, studies were carried out by active immuniza-
tion of monkeys against sheep FSH, which resulted in progressive decrease in sperm counts
with the increase in antibody titer, which took about 60-90 d.  All the monkeys were found to
be infertile when breeding studies were carried out with proven fertile females.  This was
reversible when the immunization was interrupted. The most important feature of this
approach is that the T levels and thus libido are unaffected during the entire course of study.
Thus interfering with the action of FSH appeared to be a very promising method. Based on
these results, a pilot study was undertaken to assess the responsiveness of human volunteers
to immunization against ovine FSH.  All the subjects responded to immunization by producing
specific antibodies to FSH with no changes in other glycoprotein hormones and more impor-
tantly testosterone. Seminal plasma T, a marker of Sertoli cell and seminiferous tubule function,
showed marked reduction following immunization against FSH[4].
However, this approach has some practical problems which include the availability of
sufficient quantity of recombinant FSH for large scale usage and variability in the immune
response of the subjects. It is known that the response of the subjects to immunization
against different antigens is highly variable and it is necessary to maintain the minimum
effective antibody titer in all the subjects through out the period if contraception has to be
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achieved by blocking the action of FSH.  Also there are needs for: (a) use of an alternate
method of contraception until effective titer of antibody against FSH are produced in the
serum; (b) more importantly requirement for periodic boosters to maintain the titer; (c) the
possibility of production of antibodies which may cross react with other hormones such as
LH and TSH with which FSH shares structural homology in both alpha and beta units and
together constitute the whole functional hormones.
One way to overcome the last problem was the use of receptor for FSH as the antigen
instead of FSH.  Accordingly, Moudgal, et al.[5] used the extra cellular domain of the FSH
receptor, which is involved in ligand binding, as an antigen in the adult male bonnet monkeys.
Results revealed that in these monkeys, sperm counts decreased without any effect on
serum T levels and all the immunized monkeys were infertile. Though this approach
eliminates the problem of production of antibodies to other related hormones, it still suffers
from the disadvantage of production of antibodies to other receptors for related glycoprotein
hormones since FSHR, LHR and TSHR belong to the super family of G-protein coupled
receptors.  In fact, it is known that in clinical situation both stimulatory and inhibitory
antibodies against TSHR are encountered routinely and this is a serious problem[6].
Once again an effort was made to overcome this problem also by choosing the highly
specific regions of FSH receptor which bind to FSH, but do not share any homology with
other related receptors. Three such specific peptides expressed on filamentous phages and
these phages were used as antigen in adult male bonnet monkeys. Active immunization of
proven fertile adult male bonnet monkeys against phage expressed FSH receptor specific
peptides from the extra cellular domain resulted in a progressive drop in sperm count with all
animals which became azoospermic by d 100.  However, serum T concentrations were
unaltered during the entire course of study and animals exhibited normal mating behavior[7].
Following arrest of immunization, there was a decrease in antibody titer and all the animals
exhibited normal fertility.
An important outcome of these studies is the demonstration of inhibition of spermato-
genesis and induction of infertility by neutralization of endogenous FSH without interfering
with T.
Interfering with T production and supplementation with long acting androgens
The second method is to block the production of T which will inhibit spermatogenesis
and administer sufficient quantity of T and maintain libido and secondary sexual characters.
Over the years efforts have been made by WHO to explore the possibility of using a variety
of T derivatives which act at the level of hypothalamus to inhibit the release of pituitary FSH
and LH. This in turn causes inhibition of production of T which results in inhibition of sperm
production although it interferes with libido; however, simultaneously slow releasing deriva-
tives of androgen are given to maintain the libido and secondary sexual characteristics. Two
long acting testosterone derivatives, testosterone enanthate[8] and testosterone bucyclate,
have been tested in human subjects[9].  Preliminary results suggested that the contra-
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ceptive efficacy was high even when spermatogenesis was not fully suppressed.  Based on
these observations, T was given as an implant every 4 months and progestin DMPA injected
every 3 months had been tried in 55 couples as a male contraceptive and no pregnancies
were reported over 12 months. This study provides the proof of the principle, which
male contraception by hormonal steroids is possible[10].
Blockade of T production can also be achieved by administration of GnRH agonists or
antagonists[11-14]. However, these compounds have to be given chronically and recent
studies have clearly established that GnRH has action on non-reproductive tissues.  Also,
even this approach needs supplementation with androgen and use of alternate approaches
until its efficacy is established. Considering the above problems associated with androgen
supplementation, it is unlikely that the use of GnRH agonists or antagonists as a male
contraceptive will be ever successful.
Hormonal approaches to male contraception based on the suppression of LH secretion
require androgen replacement treatment to maintain sexual behavior and secondary sexual
characteristics. Androgen supplementation not only involves large and frequent doses of T
esters but also results in undesirable effects on the prostate gland.  In an attempt to avoid
such problems, a synthetic androgen, 7-alpha-methyl-19-nortestosterone (MENT), which is
much more potent than T, has been developed.  It was reported that the potency of MENT
as an androgen was 4 times higher than that of T and anabolic effects of MENT on skeletal
muscle were 10 times higher than those of T[15]. In addition, MENT was also 12 times more
potent than T in the suppression of serum gonadotropin.  In the primate model, MENT was
10 times more potent than testosterone with regard to clinically desirable end points of
gonadotropin suppression and anabolism of MENT had been tested in the adult male bonnet
monkeys. In one of the studies, MENT was administered at different doses (25 µg/d, 50 µg/d,
100 µg/d, 300 µg/d and 1 000 µg/d) either alone or in combination with estradiol 17β (50 pg)
via silastic implants to adult male bonnet monkeys (Macaca radiata) for a specified period.
Blood and semen samples were collected at specific intervals and analysed for serum T and
seminal parameters, respectively. The results of this study clearly revealed that administra-
tion of MENT at all doses tested resulted in suppression of nocturnal surge of T (by d 3), as
well as a decrease in the number of spermatozoa (by d 45).  Simultaneous administration of
estradiol resulted in a reduction in the dose of MENT required to suppress the nocturnal
surge. None of the male bonnet monkeys treated with MENT were able to impregnate
females, clearly demonstrating the efficacy of MENT in blocking fertility of male bonnet
monkeys[16].  Preliminary studies revealed that administration of MENT even at high doses
did not have any toxic effect assessed by hematological and biochemical parameters.  Although,
being more effective than T, the libido and secondary sexual characteristics were unaffected
and there was no need for any further supplementation with androgen.  More importantly in
contrast to the large quantity of testosterone or its derivative used, MENT was effective in
very low doses.  Recently studies have been carried out in human volunteers who were
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administered MENT subdermally by implants containing MENT acetate. Subjects, who re-
ceived four implants each capable of releasing 400 µg/d became oligozoospermic to
azoospermic without any side effect[17]. The only problem is that it has to be delivered by
injection or via slow release mechanism.  If one can develop an orally active derivative of
MENT, it can fulfill the requirements of a potential male pill, although alternative methods
have to be used until the sperm counts decrease to the required level.
Interfering with sperm maturation
Active immunization against sperm antigens
It is well established that testicular sperms do not have forward motility and are inca-
pable of fertilizing egg.  Testicular sperms have to pass through the rete tubules and epididy-
mis to undergo the process of maturation which involves acquisition of forward motility and
fertilizing capacity.  In view of this, intensive studies are in progress all over the world to
understand the process of sperm maturation. Though these efforts are not completely
successful, they provide important clues.  It is demonstrated that sperm membrane under-
goes important changes during its transit through epididymis. Epididymal secretory proteins
are associated with the sperm surface during maturation and participate in the development
of fertilizing capacity of the sperms. Their role as mediators of sperm maturation is sup-
ported by the fact that addition of epididymal proteins promotes the maturation of immature
sperms by induction of fertilizing capacity and exposure of mature spermatozoa to antibodies
that are direct towards epididymal protein impede the fertilizing capacity of the spermatozoa.
Thus induction of antibodies that interfere with the association of the protein to the sperm
surface or mask these proteins on the sperm surface in the male tract and reduce the func-
tional capacity of sperm could serve as potential contraceptives. One such protein in rats
called DE 37 kD is synthesized by the epithelium of the proximal epididymis originally local-
ized in the dorsal region of sperm head and is involved in sperm egg fusion process. Active
immunization against this protein in both male and female rats led to infertility[18]. Indirect
immunofluorescence assays with spermatozoa indicated that the immune serum was
capable of recognizing DE on the fresh spermatozoa. This suggests that the circulating
antibodies have accessed in the reproductive tract, to interfere with the function of the
protein which is used as an antigen. Protein DE fulfils many of the requisites of candidate
antigen for immunocontraception and research focused towards identification of the human
functional analogues revealed that acidic epididymal glycoprotein related product (ARP)
was its functional human counterpart. Further studies using differential cDNA screening
procedure to target gene products of post-testicular origin testis as a negative control and
after secondary screening with various tissues led to the cloning of 6 human epididymal
proteins (HE1-HE6)[19,20]. With the exception of HE5 (CD52), all of these represent com-
pletely novel gene products whose expression is highly restricted to epididymis. HE1 accu-
mulates in the caudal region of epididymis, functions as cholesterol transfer protein and plays
a major role in capacitation of the sperm which involves change in cholesterol/ phospholipid
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ratio. HE2 is of caput in origin and plays a role in sperm-egg fusion. HE4 is secreted by distal
human epithelium and is a decapacitation factor. HE5 is found to be highly concentrated in
the caudal epithelium and caudal luminal fluid being a GPI anchored protein. Finally, HE6
belongs to the novel member of the 7 transmembrane domain receptor family whose ligand
is not known. The large N-terminal extracellular domain of HE6 resembles that of glycopro-
tein hormone receptors suggesting a glycoprotein originating from testicular secretion might
be a probable ligand. These novel target molecules unique to epididymis may serve as a
target for contraception either by developing specific drugs which interfere with its function
or by developing neutralizing antibodies by active immunization.
Other sperm specific proteins that have been used include SP-10, lactate dehyrogenase
(LDH-4), PH-20 and FA-I, GP-83, GP-39, YLP-12, SAMP-32 and E-3[21-24]. FA-1 has been
tested for its contraceptive efficacy where active immunization against these proteins in
monkeys and rabbits led to reduction in fertility. Studies involving 15 baboons immunized
against the immunodominant epitope of the human LDH-4 conjugated to diphtheria toxin
revealed a 75% reduction in fertility compared with control groups of animals[25].  Sperm
from LDH-4 immunized male baboons had diminished zona binding capacity[26]. The other
antigens tested in experimental animals include RSA-1, human SP17, Tcle-1, βH20 and
SP10. Recently, it has been demonstrated that one of the isozymes in sperm which is very
specifically expressed only during spermatogenesis is glyceraldehyde 3-phosphate dehydro-
genase-S (Gapds).  It is tightly bound to the fibrous sheath, a cytoskeletal structure that
extends most of the length of the sperm flagellum. Disruption of Gapds expression by gene
targeting revealed that the Gapds(-/-) males were infertile and had profound defects in sperm
motility, exhibiting sluggish movement without forward progression[27]. Although mitochon-
drial oxygen consumption was unchanged, sperm from Gapds(-/-) mice had ATP levels that
were only 10.4% of those in sperm from wild-type mice.  These results imply that most of
the energy required for sperm motility is generated by glycolysis in sperm and its depen-
dence on this sperm-specific enzyme suggest that Gapds is a potential contraceptive target,
and that mutations or environmental agents that disrupt its activity could lead to male infertility.
Similarly, the fact that the proteins of vas deferens also have an important role in sperm
function was revealed by knocking out P2X1 receptors. P2X1 receptors for ATP are ligand
gated ion channels and presented on many excitable cells including vas deferens smooth
muscle cells. A substantial component of the contractile response of the vas deferens to
sympathetic nerve stimulation which propels into the ejaculate is mediated through P2X1
receptors. Male fertility is reduced by 90% in mice with a targeted deletion of the P2X
receptor gene.  There was neither sperm dysfunction nor effect on T levels[28].
Another sperm bound antigen is riboflavin carrier protein (RCP). Riboflavin is a water-
soluble B-complex vitamin, which is essential for the embryonic growth and is transported in
the system by RCP. RCP is also involved in intratesticular vitamin transport to germ cells. In
vitro studies demonstrated that the addition of RCP antibody had profound effects on sperm
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motility. Sperms were progressively immobilized with time which was further aggravated by
addition of guinea pig serum as a source of complement, with 70% decline in penetration
capacity as assessed by zona-denuded hamster egg penetration test. Active immunization of
male rats led to significant reduction in fertility and anti-RCP antibodies could be identified in
the void spermatozoa[29]. Bonnet monkeys actively immunized against RCP revealed that
anti-RCP antibodies are indeed associated with acrosomal caps of the ejaculated spermato-
zoa and had impaired motility parameters. There was no change in the serum T and mating
studies revealed that in repeated mating with fertile females during d 10-16 of ovulatory
cycles, no pregnancies were recorded[30].
However, none of the studies have reached a stage where it could be inferred that a
particular antigen could be the candidate antigen for use as a contraceptive vaccine. Very
recently, studies of employing Eppin, which is a testis/epididymis specific protein, as a candi-
date vaccine have reported some success in adult male bonnet monkeys. Seven out of nine
males (78%) employed in the study developed high titers to Eppin (epididymal protease
inhibitor)[31]. It was observed that all of these high-titer monkeys were infertile. Five out of
seven (71%) anti- eppin titer males recovered fertility when immunization was stopped. This
study demonstrates that effective and reversible male immunocontraception is an attainable
goal.
Blockade of estrogen action
Estrogen is no longer considered as a female “only” hormone. In the adult testis, estro-
gen is synthesized by the Leydig cells and germ cells, and a relatively high concentration of
estrogen is found in rete testis fluid. Estrogen receptors exist in the testis, efferent ductules
and epididymis of most species. Disruption of the estrogen receptor alpha either in the knockout
(αERKO) or by treatment with a pure antiestrogen, results in dilution of cauda epididymal
sperm, disruption of sperm morphology, inhibition of sodium transport and subsequent water
reabsorption, increasing secretion of Cl-, and eventually decreasing fertility. In addition to
this primary function of regulation of luminal fluid and ion transport, estrogen is also respon-
sible for maintaining a differentiated epithelial morphology. This strongly suggests that estro-
gen or estrogen receptor alpha mediated action is an absolute necessity for fertility in the
male[32].
The observation that estrogen plays an important role in sperm maturation has suggested
the possibility of interfering with estrogen action at epididymal level.  Accordingly one can
use estrogen receptor antagonists to block the action of estrogen. In fact, our own studies
which involved chronic administration ICI 182870, a specific estrogen receptor antagonist, in
adult male bonnet monkey, revealed a drastic decrease in sperm motility[33].  ICI treatment in
male rats also led to decreased fertility[34]. Similarly, following chronic administration of
TMX (tamoxifen), another E2 receptor antagonist, the adult male bonnet monkeys were
found to be infertile with severe abnormalities in sperm morphology and decreased
motility[35].  TMX treatment in male rats also affected sperm fertilizing ability[36,37]. While
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these results are very encouraging one has to remember that estrogen has several sites of
action in the male including brain and unless a specific estrogen receptor blocker which is
targeted only to epididymis can be developed, this approach is not going to be practical.
While the approach of interfering with the sperm maturation process is very attractive
due to its non interference with T, this approach has the similar problems.  Majority of the
proteins which were found to be involved in sperm maturation are androgen regulated to
inhibit the production of these proteins involves interference with T. Alternatively one can
use the most promising protein as a candidate vaccine and to raise antibodies to interfere
with action of these proteins.  Also, it is accepted now that more than one antigen need to be
used to produce a successful vaccine and further studies are required to delineate the type of
immune response and its augmentation required to increase the contraceptive efficacy.
However, as in the case of using FSH, as a contraceptive vaccine, the response to the
antigen is highly variable due to genetic variability, sufficient titers which can reach the
epididymal lumen, have to be maintained by periodic injections.  The availability of sufficient
quantity of antigen and the need for frequent injections and need to use alternative ap-
proaches during early periods of immunization are major hurdles in making this approach a
reality.
Blocking passage of sperms
Blocking vas deferens by injecting styrene maleic anhydride which polymerizes in situ
has also been proposed as a method of male fertility control[38]. Vas occlusion involves injec-
tion of the desired compound through the skin to form plugs in vas deferens.  It was reported
that injection of polyurethane directly into the surgically exposed sperm duct in baboons
achieved azoospermia in most of the animals by one month[39].  The plugs were removed
surgically after 9-18 months to determine the reversibility.  A clinical study conducted in 10
men in China, revealed that most of the men achieved azoospermia or severe oligozoospermia,
although the rate of disappearance of sperm was slow. This has led to further studies to
establish whether this is related to the size of the plug or to other factors. Studies carried out
in China has provided evidence that polyurethane plugs are easily removed after 1-2 years in
place which sperms returned into the ejaculate and high rate of pregnancy could be achieved [39].
Current status
It is evident from the above cited new approaches for male contraception that consid-
erable progress has been made in developing more than one method.  However, each one
has its merits and demerits.  Among the various approaches, immunization using either FSH
or FSHR or peptides appears very attractive as the efficacy and reversibility has been clearly
established. The eradication of small pox using the mass vaccination approach has been the
main impetus for our effort to develop a contraceptive vaccine.  A contraceptive vaccine
essentially involves the use of a molecule either a protein or small ligand which has critical
role in the reproductive process. Interfering with its function by using antibodies would mean
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an impairment in reproduction. The primary requirement for a molecule to be a candidate
vaccine is that it should have an indispensable specific role in the reproductive process and
its absence should not have any adverse effect other than impairing fertility.  Besides, it
should be easy and economically viable to produce on a large scale. If we consider the above
prerequisites, many of the candidate antigens identified do not fulfill the requirements.  Several of
them are only at the stage of establishing efficacy. Only the approaches of blocking FSH
action by using FSHR peptides or the use of eppin have reached a stage of identifying the
immunogenic epitopes. It is essential to identify the epitope, as it is much easier to produce them
by chemical synthesis by recombinant technology.  Production of large proteins by recombinant
technology has inherent problems.  However, once again efficacy studies with the identified
epitopes have to be carried out.  After establishing the efficacy of the approach using the
candidate epitope(s), the appropriate adjuvants suitable for human use have to be identified
and suitable for immunization schedule have to be developed to sustain a uniform immune
response. It is very essential to realize that even after a candidate antigen is identified and
produced in enough quantities by recombinant methods, methods are developed to sustain an
effective uniform response in 100% of the subjects (which is a daunting task), the main draw
back in the application of this approach is the need for periodic injections (which will be a
major problem in developed countries with high illiteracy and rural population).  In the case
of sperm or epididymal antigen, enough antibodies should reach the site where these antigens are
present.
With regard to hormonal contraception using androgen to block hypothalamo pituitary
axis, several issues should be considered before it can be employed for mass application.
These include the assessment of side effects due to the androgens and progestins used,
particularly on the prostate as it is an androgen responsive tissue in addition to other anabolic
effects due to the steroids; the quantity and duration need for androgen supplementation and
mode of delivery as contraceptive efficacy studies by WHO revealed that there is ethnic
difference between Chinese Indonesian men and Caucasians. It was found that the former
were more susceptible to the contraceptive effects of steroids[39]. Certainly a more detailed
study is warranted with different populations.
Also azoospermia has been more difficult to achieve than oligospermia. Although the
contraceptive efficacy of azoospermia has been convincingly established the efficacy of
severe oligozoospermia is still the subject of clinical studies. The demonstration of contraceptive
efficacy of oligozoospermia is considered as one of the more critical steps towards the
development of male contraceptive.
The use of GnRH agonists or antagonists to interfere with T production and thus fertility
also needs androgen supplementation. These compounds have to be administered chronically
and recent studies have clearly established that GnRH has action on non-reproductive tissues.
With regard to the approach of interfering with sperm maturation by blocking estrogen
action at the level of epididymis, an appropriate selective estrogen receptor modulator (SERM)
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has to be developed which can be targeted only to epididymis without any side effect on the
other estrogen responsive tissues[40-42].  Although this is certainly feasible, it is still a long way
to go before it can find practical application.
The use of agents to block the passage of sperms in vas deferens is attractive but can
only be considered as a modification of vasectomy and needs surgical skills for the applicator.
The reversibility also has to be assured.
Concluding remarks
The practical application of methods of male contraception based on the above findings
is not going to be reality in the near future. The time frame for any of the approaches
discussed above for practical use cannot be defined.  Among the various approaches, the
use of MENT has more promise as it is very effective at very low doses and does not need
androgen supplementation. MENT or more effective derivatives can be administered by a
slow release mechanism in such a way that one administration is adequate for one year.
Similarly, the approach of active immunization against sperm antigen, epididymal antigens,
FSH or FSHR peptides opens up the possibility of investigating the interaction between the
receptor with its ligand so that a small non-toxic non-peptide organic compound which can
inhibit the interaction can be developed as in the case of SERM.  Even if any one of these
methods are successful, one is always faced with the problem of need for an alternate
approach until one can rely on the efficacy of the method, making it not a very friendly user
approach. Considered this, the option left for male contraception for the time being is the age
old approach of barrier method or vasectomy.
The opinions expressed in this article are of the author’s own and funding agencies are
not responsible.
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